The purpose of the study is to determine whether Brenipatide can improve lung function compared with placebo in adults with COPD. Lung function is mainly assessed by measuring the change from the start of the trial in the amount of air a person can force out of the lungs in one second, known as Forced Expiratory Volume in 1 Second (FEV1). This measurement helps to understand how well the lungs are working.

Participants will be randomly assigned to receive either the study drug or placebo for approximately one year, with regular clinic visits to receive the injection, monitor health, and check for any side effects. Throughout the study, safety checks and simple breathing tests will be performed to gather information on how the treatment affects the disease.

The trial compares an oral capsule of the experimental drug Lu AF28996 with a matching placebo to see if it can increase the amount of good “ON” time and reduce “OFF” time and troublesome dyskinesia. Participants will take the assigned capsule for about 19 weeks, record their daily experiences in a simple diary, and attend a few clinic visits for safety checks. The purpose is to assess whether the drug improves motor complications in people with Parkinson’s disease. In this context, “ON time” means periods when symptoms are well controlled, “OFF time” means periods when symptoms return, and “dyskinesia” refers to involuntary movements that can be bothersome.

The purpose of the trial is to compare the effect of adding the new drug to usual treatment versus adding a placebo. Patients receive a combination of chemotherapy that may include irinotecan, oxaliplatin, paclitaxel albumin-bound, gemcitabine, fluorouracil, and calcium folinate hydrate. The oral study medication or the placebo is taken each day, while the chemotherapy drugs are given through an IV infusion on scheduled days.

Participants are randomly assigned to one of the two groups and neither they nor the doctors know which group they are in. Treatment cycles are repeated every few weeks, with regular visits for drug administration, blood tests, and imaging scans to check the tumor. The study continues until the disease progresses, side effects require stopping treatment, or a predefined period of follow‑up is completed.

Participants will be randomly assigned to receive either the active medication or the placebo, and neither the participants nor the study staff will know which treatment is being given (double‑blind). This is a phase 2 trial, meaning it is an early test of how well the drug works and how safe it is. After taking the tablets daily, subjects will attend a few clinic visits over about four months, during which doctors will count the facial lesions and evaluate overall skin appearance using a simple grading system. Any side effects that arise will be recorded throughout the study period.

The purpose of the trial is to determine whether survodutide can lower the risk of serious liver‑related events and death in people with compensated cirrhosis due to NASH/MASH. Participants will receive the study injection each week for about a year and will attend regular clinic visits for safety checks, blood tests, and imaging. The main outcome looks at the time until the first occurrence of any major event such as liver transplant, death, hepatic decompensation (a worsening of liver function), a rise in the MELD score (a number that reflects how well the liver works) to 15 or higher, or the development of CSPH (high blood pressure in the vessels of the liver). Additional measurements include changes in the ELF score (a blood test that indicates liver scarring), body weight, blood sugar levels, and liver stiffness assessed by FibroScan (an ultrasound that measures how firm the liver is) and MRE (a type of MRI scan for the same purpose). Blood tests will also track liver enzymes AST and ALT, which rise when liver cells are damaged.

The main goal of the trial is to find out whether survodutide can improve liver health better than the placebo. “Improving liver health” means the disease may disappear without the scar tissue getting worse, and the scar tissue may become less severe. Terms such as MRI refer to a scan that uses magnets to create detailed pictures of the liver, while VCTE is a quick test that measures how stiff the liver is, which helps doctors see how much scarring is present.

Participants will receive the weekly injection for about one year and will attend regular visits where blood samples are taken, weight is measured, and imaging tests such as MRI and VCTE are performed. After the treatment period, they will continue to be followed for several more months to monitor long‑term safety and any changes in liver condition.

The purpose of the study is to find out if Brenipatide can help reduce severe asthma attacks compared to placebo. A severe asthma attack, also called an exacerbation, is when asthma symptoms suddenly get much worse and may require treatment with oral steroids or even a hospital visit. The study will measure how many severe asthma attacks happen over the course of the treatment period.

The study will last for 52 weeks, which is about one year. People taking part will be randomly assigned to receive either Brenipatide or placebo, and neither they nor their doctors will know which treatment they are getting during the study. Throughout the study, doctors will monitor how well the treatment works and check for any side effects. To join this study, people must have been diagnosed with asthma and have been taking asthma controller medication for at least 12 months, and they must have had at least one severe asthma attack that required oral steroid treatment in the past year.

The purpose of the study is to find out if depemokimab works better than placebo in treating people with this lung disease who have a type of inflammation called Type 2 inflammation. The study will look at whether the medication can reduce the number of times symptoms suddenly get worse, which doctors call exacerbations. These are times when breathing problems become much worse and may need treatment with antibiotics or steroid pills, or sometimes even a visit to the emergency room or hospital.

During the study, people will receive treatment for up to 104 weeks, which is about two years. The doctors will check how often breathing problems get worse, how long it takes before problems get worse, and how the disease affects daily life and breathing symptoms. The study will compare results between people receiving depemokimab and those receiving placebo to see if the medication helps reduce flare-ups and improves quality of life for people with this lung condition.

Participants will be randomly assigned to receive either one of several dose levels of the study drug or a placebo, and neither the participants nor the study staff will know which treatment each person receives (double‑blind). Over about 12 weeks, participants will take the tablet each day and attend regular visits where their skin will be examined, they will answer questions about itch and daily life, and basic safety checks such as blood tests and heart monitoring will be done. The main result that will be measured is the change in a scoring system called EASI, which rates how much of the body is affected and how severe the rash is.

The purpose of the study is to find out if felzartamab works better than placebo in treating this type of inflammation in transplanted kidneys. The study will also look at whether the medication is safe and how it affects kidney function over time. The inflammation is identified through a kidney biopsy, which is a procedure where a small piece of kidney tissue is examined under a microscope. The study will check if the medication can reduce or eliminate the inflammation seen in the biopsy and whether it can help maintain or improve how well the transplanted kidney is working.

The study is divided into different parts and will last for about one year for each participant. During this time, participants will receive the study medication or placebo through infusions at scheduled visits. Throughout the study, participants will have regular check-ups that include blood tests, urine tests, measurements of vital signs like blood pressure and heart rate, and tests to check how well the kidney is functioning. Another kidney biopsy will be performed during the study to see if there are any changes in the inflammation. The study will also monitor for any side effects or unwanted reactions to the medication.

The purpose of the study is to evaluate how effective Felzartamab is in treating patients with active or chronic active AMR. Participants in the study will receive either Felzartamab or a placebo through an intravenous infusion, which means the medication is given directly into a vein. The study will last for a period of up to 12 months, during which participants will have regular visits to monitor their health and the effects of the treatment.

In addition to Felzartamab, the study will also use a Saline Solution for infusion, which is a simple saltwater solution often used in medical treatments. The study aims to gather information on the safety and effectiveness of Felzartamab in improving the condition of kidney transplant recipients experiencing AMR. Participants will be closely monitored throughout the study to ensure their well-being and to collect data on how the treatment affects their condition.

The purpose of the study is to determine whether the 20 mg dose leads to greater weight loss compared with placebo. Participants receive the assigned injection once every few weeks for a period of about nine months, with clinic visits at regular intervals to record changes in body weight and other health measures. During the study, health professionals will monitor changes in HbA1c, fasting plasma glucose, waist circumference, blood pressure, cholesterol and triglycerides to assess overall safety and effectiveness.

The aim is to describe how different patients experience the disease, how well their symptoms are controlled, and how the medicine and other treatments are used over time. Participants will be asked to attend regular visits where information about their health, use of inhalers, and any flare‑ups will be recorded, and simple breathing tests will be done to check changes in lung function. Blood or breath samples will also be collected to measure biomarkers that indicate the level of airway inflammation.

Over the study period, people will complete questionnaires about daily activities, sleep, and how asthma affects work or school, and doctors will note any visits to emergency services or hospitals. The collected data will help understand the relationship between the measured inflammation markers and the way symptoms change, without requiring any experimental procedures beyond routine care.

The purpose is to determine whether the monthly treatment can achieve greater weight loss than the placebo over a period of about 72 weeks. Participants are randomly assigned to receive either the medication at one of several dose levels or the placebo, and neither the participants nor the study staff know which is administered. Injections are given every four weeks, and participants attend regular clinic visits where their weight, waist size, blood pressure, and physical function are measured.

The main goal is to evaluate the long‑term safety and tolerability of the drug. After enrollment, participants will continue taking the tablet for up to one year, returning for regular check‑ins where doctors will look for any side effects and will assess lung function using a test called FEV1, which measures how much air can be exhaled forcefully in one second. Symptom control will be measured with a short questionnaire known as the ACQ-5, and overall quality of life related to asthma will be evaluated with the AQLQ(S) questionnaire. These visits help ensure participants are monitored closely while remaining on the study medication.

During the study, participants have regular check‑ups that include blood tests, a scan called MRI (which creates detailed pictures of internal organs) to measure spleen and liver size, and assessments of blood‑carrying protein (hemoglobin) and tiny blood‑clotting cells (platelet count). A questionnaire that looks at everyday skills and motor abilities is also completed. Blood samples are taken to measure substances that indicate disease activity, and any side effects or safety concerns are recorded throughout the study period.

The purpose of the study is to find out if the under‑skin injection works at least as well as the vein infusion in terms of how the drug moves through the body (pharmacokinetic). Participants are randomly assigned to one of the two ways of receiving the medicine and will visit the clinic regularly for blood tests, imaging scans to see the tumor, and safety checks. The trial lasts for several months, during which any side effects are recorded and managed.